Citigroup resumed coverage on IMARA with a new price target
$IMRA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Citigroup resumed coverage of IMARA with a rating of Buy and set a new price target of $30.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/6/2022 | $12.00 → $4.00 | Equal-Weight | Morgan Stanley |
| 11/30/2021 | $10.00 | Buy | HC Wainwright & Co. |
| 8/11/2021 | $33.00 → $12.00 | Overweight → Equal-Weight | Morgan Stanley |